| N/A | Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment | 409159 | 2010 | Co-Investigator | | Dr Wang Julie | Co-Investigator | | Dr Wong Matthew | Co-Investigator | | Dr Lam Jamie | Co-Investigator | | |
| Principal Investigator (PI) | | |
|
| N/A | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC) | 221926 | 2010 | Co-Investigator | | Dr Wong Matthew | Co-Investigator | | | Co-Investigator | | Dr Lam Jamie |
| Principal Investigator (PI) | | |
|
| N/A | Open label, prospective, double arm, randomized, pilot study to evaluate the safety and efficacy of the same day administration of PDT with verteporfin and an intravitreal injection of ranibizumab vs. ranibizumab monotherapy for the treatment of subfoveal CNV secondary to neovascular age related macular degeneration in the Asian population | 500000 | 2007 | Co-Investigator | | Dr Li Kenneth Kai Wang | Co-Investigator | | | Co-Investigator | | | Co-Investigator | | Miss Chan Wing Suet Catherine | Co-Investigator | | |
| Principal Investigator (PI) | | |
|
| N/A | Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus | 51616 | 2010 | Co-Investigator | | | Co-Investigator | | | Co-Investigator | | Dr Wong King Yan Matthew | Co-Investigator | | Dr Lam Chung Mei Jamie |
| Principal Investigator (PI) | | |
|
| N/A | Phase 2, open-label single arm study of the efficacy and safety of PF 02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus | 90458 | 2010 | Co-Investigator | | | Co-Investigator | | Dr Wong King Yan Matthew | Co-Investigator | | Dr Lam Chung Mei Jamie | Co-Investigator | | |
| Principal Investigator (PI) | | |
|
| N/A | A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens. | 354319 | 2009 | Co-Investigator | | | Co-Investigator | | Dr Wang Kwan Ling Julie | Co-Investigator | | Dr Lam Chung Mei Jamie | Co-Investigator | | Dr Wong King Yan Matthew |
| Principal Investigator (PI) | | |
|
| N/A | Study of immunopathogenesis of multiple sclerosis and neuromyelitis optica | 200000 | 2011 | Co-Investigator | | Dr Chang Shek Kwan Richard | Co-Investigator | | | Co-Investigator | | Dr Pang SYY |
| Principal Investigator (PI) | | |
|
| N/A | A multicenter randomised double blind placebo controlled study of AMG785 in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture status post definitive fracture fixation with an intramedullary nail | 101741 | 2010 | | Principal Investigator (PI) | | |
|
| N/A | International, randomized, open-label, phase 3, trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first line treatment of patients with advanced non-small cell lung cancer | 30768 | 2006 | | |
| N/A | A 12-week, double-blind, randomized study to investigate the effect of 500mcg roflumilast tablets once daily versus placebo on pulmonary function in patients with chronic obstructive pulmonary disease | 178819 | 2005 | | |
| N/A | A rabdomized, double blind, placebo controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer | 288359 | 2007 | Co-Investigator | | Dr Lam David Chi Leung | Co-Investigator | | Dr Wong Matthew King Yan | Co-Investigator | | Dr Wang Julie Kwan Ling |
| Principal Investigator (PI) | | |
|
| N/A | A phase III, randomized, double-blind, active-controlled, parallel-group study, conducted under in-house building conditions, to examine the safety, tolerability, and efficacy of a single dose of intravenous MK-0517 for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated wtih Cisplatin chemotheray | 79444 | 2008 | Co-Investigator | | Dr Lam Jamie Chung Mei | Co-Investigator | | Dr Lam David Chi Leung | Co-Investigator | | Dr Wong Matthew King Yan | Co-Investigator | | Dr Wang Julie Kwan Ling |
| Principal Investigator (PI) | | |
|
| N/A | A Phase III, radonmized, double-blinded, parallel group, multi centre study to access the efficacy and safety of ZD6474 (ZACTIMA TM) in combination with pemetrexed (Alimta) versus pemetrexed alone in patients with locally-advanced or metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) after failure of 1st line anti-cancer therapy | 337838 | 2006 | Co-Investigator | | Dr Wang Julie Kwan Ling | Co-Investigator | | Dr Lam David Chi Leung | Co-Investigator | | Dr Wong King Yan Matthew |
| Principal Investigator (PI) | | |
|
| N/A | A Phase 3, multicentre, randomized, placebo-controlled, double-bind trial of AMG 706 in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer | 800615 | 2007 | Co-Investigator | | Dr Wong Matthew King Yan | Co-Investigator | | Dr Lam Jamie Chung Mei | Co-Investigator | | Dr Wang Julie Kwan Ling | Co-Investigator | | Dr Lam David Chi Leung |
| Principal Investigator (PI) | | |
|
| N/A | A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/V non-small cell lung cancer (NSCLC) | 358316 | 2008 | Co-Investigator | | Dr Wang Julie Kwan Ling | Co-Investigator | | Dr Lam David Chi Leung | Co-Investigator | | Dr Wong Matthew King Yan | Co-Investigator | | Dr Lam Jamie Chung Mei |
| Principal Investigator (PI) | | |
|
| N/A | A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7,5mg.kg or 15mg/kg) in addition to carboplain-based chemotherapy (gemcitabine or paclitaxed) | 271260 | 2008 | Co-Investigator | | Dr Lam David Chi Leung | Co-Investigator | | Dr Lam Jamie Chung Mei | Co-Investigator | | Dr Wang Julie Kwan Ling | Co-Investigator | | Dr Wong Matthew King Yan |
| Principal Investigator (PI) | | |
|
| N/A | Multicenter, randomized, double-blind, phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy | 328733 | 2008 | Co-Investigator | | Dr Wang Julie Kwan Ling | Co-Investigator | | Dr Lam Jamie Chung Mei | Co-Investigator | | Dr Wong Matthew King Yan | Co-Investigator | | Dr Lam David Chi Leung |
| Principal Investigator (PI) | | |
|
| N/A | A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | 606761 | 2010 | Co-Investigator | | Dr Wong Matthew | Co-Investigator | | | Co-Investigator | | Dr Lam Jamie |
| Principal Investigator (PI) | | |
|
| N/A | A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM | 207773 | 2011 | Co-Investigator | | | Co-Investigator | | Dr Wong Matthew | Co-Investigator | | Dr Lam Jamie |
| Principal Investigator (PI) | | |
|
| N/A | Gene therapy for diabetic nephropathy using ultrasound-microbubble-mediated transfer of inducible smad7 | 193737 | 2006 | | Principal Investigator (PI) | | Professor Lan, Hui Yao |
|
